Plasma biomarkers for lung cancer diagnosis

项目摘要-摘要 由于低剂量CT(LDCT)早期发现肺癌可以降低死亡率， 医疗保险和医疗补助服务中心现在正在报销每年一次的LDCT筛查 (CMS)适用于通过联邦医疗保险参保的吸烟者。然而，超过四分之一的屏幕 发现不明肺结节(PNS)。4%的PNS是早期肺癌，而 剩下的96%是良性的。因此，LDCT有过度诊断的可能。有一种未得到满足的需求 反射测试用于LDCT随访，以重点关注4%需要它的吸烟者。这样做的目的是 该项目是开发和验证一种血浆测试，以区分恶性和良性PNS在 基线LDCT。未来使用这一测试来区分恶性和良性PNS将 补充LDCT用于肺癌检测，减少过度诊断，最终 降低死亡率和成本。

Project Summary-Abstract Because the early detection of lung cancer by low-dose CT (LDCT) can reduce the mortality, annual LDCT screening is now being reimbursed by Centers for Medicare & Medicaid Services (CMS) for smokers insured through Medicare. However, more than one-quarter of screens discover indeterminate pulmonary nodules (PNs). 4% of PNs are early-stage lung cancers, while the remaining 96% are benign. Therefore, LDCT has over-diagnosis. There is an unmet need for a reflex test for LDCT follow-up to focus care on the 4% smokers need it. The objective of this project is to develop and validate a plasma test for differentiating malignant from benign PNs at baseline LDCT. Future use of this test for discriminating between malignant and benign PNs will complement LDCT for lung cancer detection by reducing the over-diagnosis, and eventually decrease the deaths and cost.